51 results about "Immune markers" patented technology

An efficient, objective, flexible and easily deployable system for conducting evaluations of mental and physiological state and recommending individualized treatment to improve said state is described. The method and system are based on commensurate measurement of mental functions, levels of stress and anxiety, and / or biologically active molecules such as neurotransmitters, immune markers including cytokines and hormones. The method and system are designed to assess an individual's cognitive function and the underlying physiology in order to delineate various disease processes, injuries, drug states, training stages, fatigue levels, stress levels, aging processes, predict susceptibility to stress and / or sleep deprivation, identify aptitude for training and / or characterize effects of any experimental conditions. The system and method may be used in recommending individualized treatment protocols, as well as to guide the treatment process by assessing the efficacy of such therapies in the clinical trials process.

The invention belongs to the technical field of analytical chemistry and chemical sensors and discloses an electrochemical immunosensor for detecting a toxoplasma gondii IgM (Immunoglobulin m) antibody (Tg-IgM) of a gravida and a preparation method of the electrochemical immunosensor. The immunosensor is prepared by sequentially modifying graphene, polythionine, gold nanoparticles and capture antigen to the surface of a glassy carbon electrode. An enzyme-functionalized nano-composite detection probe with an electrical signal amplifying function is prepared by assembling enzyme and a second antibody with high proportions on an Au-Fe3O4 surface. According to the sandwich immunoassay principle, the concentration of Tg-IgM is determined by using an electrochemical signal generated by catalysis of enzyme to a substrate. According to the electrochemical immunosensor, the specificity of immunoreaction is combined with the sensitivity of electrochemical detection; the transmission of electronics is promoted by using the graphene, the polythionine, the gold nanoparticles, Au-Fe3O4 and other material; and the sensitivity of the detection is improved. The electrochemical immunosensor has the advantages of simplicity and convenience for operation, favorable regeneration performance and detection cost reduction. The electrochemical immunosensor prepared on the basis can be also used for detecting other immunological markers and has favorable application prospect in medical diagnosis.

Described herein are compounds (including medical foods, pharmaceutical compositions, methods of compounding them), methods and systems for the diagnosis and / or treatment of prodromal schizophrenia. For example, described herein are methods of treating a developmentally-based neuropsychiatric disorder (schizophrenia) that includes first determining if a subject is at risk for such a disorder by examining phenotypical, serological immune markers and genotypical biomarkers. The biomarkers may be used to tailor the dose to be delivered by the medial food or pharmaceutical composition. Also described are compounds for treating prodromal (rather than full-blown) schizophrenia.

The invention provides a method for detecting the content of an immunomarker and a kit. The method comprises the following steps: a), preparing magnetic nanoparticles, the surfaces of which are modified with immunomarker antigens; b) preparing fluorescent quantum dots, the surfaces of which are modified with immunomarker antibodies; c) detecting the content of the immunomarker: uniformly mixing ato-be-detected sample containing the immunomarker with the magnetic nanoparticles modified with the immunomarker antigen in the step a), and adding quantum dots modified with an immunomarker antibodyfor incubation; d) performing magnetic separation to remove the magnetic nanoparticle-quantum dot immune complex and the remaining uncombined antigen-modified magnetic nanoparticles; e) measuring thefluorescence intensity of the supernate or the redissolved magnetic nano immune complex to obtain the content of the immune marker in the to-be-detected sample. By utilizing the method disclosed by the invention, the detection sensitivity and the detection efficiency of the serum marker can be remarkably improved, and the sensitive, efficient, rapid and convenient detection requirements on the marker are met.

The invention provides a tumor detection data analysis method based on a peripheral blood immune marker, and belongs to the technical field of immunodetection.The tumor detection data analysis method comprises the steps that firstly, a peripheral blood sample of a patient is collected, and plasma and cell components are separated; analyzing various immune cell phenotypes by using flow cytometry; determining the concentration of key cell factors; analyzing the molecular expression level of the immune checkpoint; establishing an immune cell subset proportion empirical function; analyzing a cell factor expression mode by using an immune lineage transcriptome analysis model; establishing a tumor immune microenvironment score by combining the immune cell subset proportion and a model output result; the accuracy of the scoring system is verified through clinical follow-up visit and iconography examination; a standardized report template is formulated to provide a tumor early detection basis. Wherein the immune lineage transcriptome analytical model adopts a multi-modal attention fusion network architecture, three different immune data streams can be processed and integrated at the same time, and accurate evaluation of tumor-related immune states is realized.

This invention discloses using SPR technology to simultaneously and quantitatively measure the concentrations of diabetes related immunological makers in a serum sample, which can be used to diagnose and / or early diagnose diabetes as well as to predict the onset risk of diabetes in first-degree relatives. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of relevant antigens and antibodies used for the detection of respective diabetes related immunological makers in a serum sample.

A method for establishing a computer-aided data interpretation model for immune diseases by immunomarkers and visualization is revealed. First combine a plurality of immunomarkers into an immunomarker panel. Then collect test data of a plurality of subjects measured by the immunomarker panel, and disease diagnosis information of the subjects for establishment of an immunomarker-panel testing database. Next new subjects are tested by the immunomarker panel. The data obtained and the corresponding information in the immunomarker-panel testing database are processed by unsupervised machine learning algorithm to get a computer-aided data interpretation model showing comparison of case distribution patterns. The method provides real-time analysis of multiple data to medical professionals for their reference. Thereby the correctness, the timeliness and the reproducibility of the interpretation result for the diagnosis and treatment of immune diseases are all improved.

The invention relates to the technical field of medical radiotherapy, in particular to a tumor radiotherapy dose optimization method based on a biomarker, which comprises the following steps: S1, biomarker collection: collecting tumor tissues and blood samples of a patient to obtain biomarker data related to a tumor radiotherapy effect; s2, data preprocessing: preprocessing the collected biomarker data; s3, constructing an initial radiotherapy dose optimization model: constructing the initial radiotherapy dose optimization model; s4, immune marker monitoring and dose adjustment: monitoring the change of the immune marker of the patient in real time, and dynamically adjusting the initial radiotherapy dose; and S5, treatment effect evaluation: comprehensively evaluating the treatment effect, and judging the effectiveness of the current treatment strategy. According to the invention, the accuracy and flexibility of radiotherapy are enhanced, the side effects of an immune system are effectively reduced, and immune regulation in the radiotherapy process is optimized.

The invention relates to a preparing method and application of a ceftiofur quick time-resolved fluorescence lateral flow immunoassay quantitative detection test strip. The test strip is composed of three parts of the Fusion5 membrane, the nitrocellulose membrane and the water absorbing paper. Through a competition law principle, time-resolved fluorescence microspheres are utilized as immune markers, and to-be-tested antigens are accurately and quickly detected quantitatively.

This invention discloses using SPR technology to simultaneously and qualitatively measure the presence of HCV-associated immunological markers in a serum sample for the diagnosis of HCV infection. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of HCV related antigen proteins used for the diagnosis of HCV infection.

The invention relates to the use of biomarkers for predicting the response to cancer (e.g. melanoma) treatments, for selecting a treatment for a cancer patient (e.g. using targeted therapy, e.g. using a BRAF and / or MEK inhibitor), for stratifying cancer patients into different treatment groups, for treating cancer patients, and for predicting clinical outcome in cancer.

The invention discloses a recombinant strain for Brucella melitensis provided with an immune label. The recombinant strain for the Brucella melitensis provided with the immune label is a strain obtained by killing encoding genes of ATP conjugated protein of an O antigen output system in the Brucella melitensis. Compared with an original strain, the obtained strain has lower virulence, and can be used as a vaccine to immunize animals without killing the genes. By utilization of the strain to immunize a mouse, immunoreaction states different from those of the standard strain and the prior vaccine strain can be generated in the body of the mouse, and sicken animals can be identified from immune animal groups by immunological detection of serum of the animals. The modification of the brucelliasis vaccine and the research of a diagnosis and identification agent have important significance in developing a brucelliasis gene deletion marker vaccine and a matched diagnosis and identification agent and promoting the elimination and purification of brucelliasis of the animals all over the world.

This invention discloses using SPR technology to simultaneously and qualitatively detect the presence of respiratory tract viruses-related immunological markers in a serum sample, which can be used for the diagnosis of respiratory tract infections. It also discloses an efficient formula to make a mixed SAM that can greatly enhance the immobilization ability of the metal surface in SPR based techniques, which is good for the immobilization of representative antigens used to detect the respective respiratory tract viruses-related immunological markers (antibodies) in blood for the diagnosis of respiratory tract infections.

The present invention relates to the field of biological data processing, and discloses a lung cancer immune marker analysis method, device, electronic device and storage medium, wherein the method comprises: using fluorescent signal amplification technology to perform a multi-biomarker staining operation on lung tumor tissue to obtain a tissue staining image set; performing real cell selection on the tissue staining image set according to the region of interest input by the user to obtain a circled image set; performing quantitative statistics on each biomarker in the circled image set according to a preset optimal positive threshold screening strategy to obtain the tissue marker positive rate, interstitial marker positive rate and double positive rate between target biomarkers corresponding to each biomarker; and outputting the tissue marker positive rate, interstitial marker positive rate and double positive rate in a structured manner to obtain lung immune marker positive data. The main purpose of the present invention is to improve the comprehensiveness and accuracy of biomarker analysis of the lung cancer immune microenvironment.

A method for establishing a computer-aided data interpretation model for immune diseases by immunomarkers and visualization is revealed. First combine a plurality of immunomarkers into an immunomarker panel. Then collect test data of a plurality of subjects measured by the immunomarker panel, and disease diagnosis information of the subjects for establishment of an immunomarker-panel testing database. Next new subjects are tested by the immunomarker panel. The data obtained and the corresponding information in the immunomarker-panel testing database are processed by unsupervised machine learning algorithm to get a computer-aided data interpretation model showing comparison of case distribution patterns. The method provides real-time analysis of multiple data to medical professionals for their reference. Thereby the correctness, the timeliness and the reproducibility of the interpretation result for the diagnosis and treatment of immune diseases are all improved.

The invention relates to the technical field of detection equipment, and discloses a biochemical blood coagulation and immunity integrated analyzer which comprises a shell, a biochemical blood coagulation detection module and an immunity detection module which are arranged in the shell, a biochemical blood coagulation detection port and an immunity detection port which are formed in the front surface of the shell, and a baffle plate arranged at an opening of the biochemical blood coagulation detection port, the heat dissipation channel is formed in the side face of the shell, and the biochemical blood coagulation detection module extends out of the immunodetection module. According to the biochemical blood coagulation and immunity integrated analyzer, the biochemical blood coagulation detection module and the immunity detection module are integrated in the shell, multiple devices do not need to detect for several times, integrated detection of biochemical, blood coagulation and immune markers is achieved, the detection efficiency is greatly improved, and the medical cost is reduced; based on the advantages of portability of microfluidics and high sensitivity of fluorescence immunoassay, POCT scene requirements are met, the sample dosage and detection time consumption are reduced, and support is provided for rapid clinical diagnosis.

The present invention relates to the field of feature extraction technology, specifically to a feature extraction method and system for CAR-NK cell data, comprising the following steps: collecting CAR-NK cell samples, performing protein analysis on the CAR-NK cell samples in batches, recording changes in protein expression in each batch of CAR-NK cell samples, and performing quantitative analysis on metabolite samples to obtain metabolite concentration data, and standardizing the concentration data to obtain basic data of the cell samples. In the present invention, by quantitatively analyzing proteins and metabolites in CAR-NK cell samples, the response characteristics of cells under different immune environments can be fully captured, immune response grouping and cluster analysis clarify the impact of the immune environment on cell function, the protein-metabolite interaction network reveals the interaction between molecules inside and outside the cell, and by screening and verifying immune markers, provides an accurate basis for immune function assessment. The quantitative analysis of immune reactivity characteristics can track the immune response process in real time, thereby improving the accuracy and depth of research.

This invention discloses a detection kit and identification method for CTCs based on SCLC molecular typing using microfluidic chips and multiplex immunofluorescence probe technology. The kit includes a microfluidic chip, a biotin-labeled trapping agent, a balanced salt solution, a tissue cell fixation solution, a specific hybridization blocking solution, an active nuclear staining solution, and a diluent. It also includes a detection agent composed of key subtype markers of SCLC labeled with different fluorescein groups, SCLC-related marker detection antibodies, and leukocyte auxiliary identification markers, or a detection agent composed of key subtype markers of SCLC labeled with different fluorescein groups and leukocyte auxiliary identification markers. This application enables non-invasive, early, and sensitive detection and analysis of the expression of four immunomarkers involved in CTCs in the peripheral blood of patients: ASCL1, NEUROD1, POU2F3, and YAP1. It is suitable for early tumor screening and can also be used for pan-cancer immunotherapy guidance, immunotherapy efficacy monitoring, and prognostic assessment.

The application discloses a flexible injectable organic electrochemical transistor sensor for protein immunological marker detection and a preparation method and application thereof, and relates to the technical field of biochemical sensors, and comprises a bottom flexible substrate, a metal source electrode, a metal drain electrode and a metal gate electrode arranged on the surface of the flexible substrate, and a top encapsulation layer, wherein an organic semiconductor conductive channel is arranged between the metal source electrode and the metal drain electrode, the metal gate electrode is arranged in a coplanar mode with the organic semiconductor conductive channel, the top encapsulation layer plays an encapsulation role, and the organic semiconductor conductive channel and the metal gate electrode are exposed after encapsulation; the metal gate electrode is modified with a monolayer of 11-mercapto undecanoic acid self-assembly, and an amino-modified single-stranded DNA molecule aptamer is covalently coupled on the monolayer. The sensor can be used for detection of various protein molecules including IFN-gamma tumor markers.

The invention relates to the use of biomarkers for predicting the response to cancer (e.g. melanoma) treatments, for selecting a treatment for a cancer patient (e.g. using targeted therapy, e.g. using a BRAF and / or MEK inhibitor), for stratifying cancer patients into different treatment groups, for treating cancer patients, and for predicting clinical outcome in cancer.

The invention discloses a gastric cancer prognosis prediction method, prognosis of a gastric cancer patient is predicted through a trained gastric cancer prognosis model, and construction of the gastric cancer prognosis model is based on myeloid reaction scoring. The construction of the gastric cancer prognosis model comprises screening of gastric cancer myeloid immune markers including a plurality of myeloid cell markers and a plurality of immune checkpoints. And by using a Lasso-Cox regression model, concluding and screening a lambda value on the premise of selecting the optimal model, and determining the number of features of which the importance is not zero and the weight of each feature through the selected lambda value to obtain a gastric cancer myeloid response score MRS.

The invention discloses a lightweight bone loss tester based on an immune marker, and relates to the technical field of medical instruments, the lightweight bone loss tester comprises a shell, the top of the shell is provided with a display screen, and the shell is internally provided with a sample introduction mechanism for controlling a to-be-detected sample to enter and exit from the shell. Firstly, a sample to be detected is fed into the shell under the action of the sample injection mechanism, then under the action of the pipetting mechanism, the pipetting mechanism is used for sucking the sample to be detected and putting the sample into the detection mechanism, and under the action of the detection mechanism, immune markers contained in the sample to be detected are detected; the bone loss risk is evaluated by combining parameters such as the age and the gender of a patient, and under the condition that the detection effect is ensured, the inspection operation is simplified, the equipment structure is simplified, and the purpose of light weight is achieved, so that the purposes of reducing the cost, shortening the waiting time and meeting the requirements of short-term and dynamic monitoring of some patients are achieved.

The application discloses a kind of for in-vivo tumor microenvironment magnetic heat immune closed loop system and control method, belong to biomedical engineering and nanotechnology cross field.For the existing magnetic heat therapy technology cannot carry out real-time self-adaptive regulation according to the dynamic change of GAL-1, IFN-gamma, IL-4 and Th1 / Th2 ratio in tumor microenvironment, easy to cause the problem that immune marker deviates from window, a kind of magnetic heat immune closed loop regulation system is proposed.Firstly, baseline value is obtained and target concentration window is set;Control alternating magnetic field to activate vortex magnetic iron oxide nanoparticles to generate heat and active oxygen;Real-time acquisition of immune marker concentration fed back by implantable electrochemical sensor, dynamically adjust field strength and / or frequency;With single effective activation window, maximum single time length, temperature as stop criterion;After stop, standby and pulse reset.Real-time self-adaptive regulation of in-vivo immune state is realized, immune activation deficiency or immune marker deviation from window is avoided, and normal tissue thermal damage is prevented by multi-level thermal safety constraint.

The invention relates to the technical field of tumor diagnosis and immunohistochemical detection, and discloses a PD-L1 immunohistochemical detection kit and method.The kit is composed of a double-epitope high-affinity antibody, a color developing reagent, a signal amplification system, antigen repair liquid, a sealing reagent and the like. According to the detection method, a double-epitope antibody is combined with different active epitopes of PD-L1 in a targeted manner, the color development effect of a weak signal area is enhanced through a Tyramide dynamic signal amplification technology, meanwhile, the spatial distribution characteristics of PD-L1 and other immune markers are analyzed by introducing a multi-target fluorescence labeling technology, a multi-dimensional scoring model is established, and the tumor immune microenvironment is comprehensively evaluated. According to the method, the sensitivity and specificity of PD-L1 detection are improved, background noise interference is reduced, the problems of leak detection of a weak positive region, cross interference of multi-target detection, inaccurate single scoring model and the like are solved, and the method is widely applied to the fields of tumor immunotherapy adjoint diagnosis and microenvironment research.

The invention discloses a flexible injectable organic electrochemical transistor sensor for protein immune marker detection and a preparation method and application thereof, and relates to the technical field of biochemical sensors, the flexible injectable organic electrochemical transistor sensor comprises a bottom flexible substrate, a metal source electrode, a metal drain electrode and a metal grid electrode which are arranged on the surface of the flexible substrate, and a top packaging layer, an organic semiconductor conductive channel is arranged between the metal source electrode and the metal drain electrode, the metal grid electrode and the organic semiconductor conductive channel are arranged in a coplanar manner, the top packaging layer plays a role in packaging, and the organic semiconductor conductive channel and the metal grid electrode are exposed outside after packaging; the metal gate is modified with a monomolecular layer formed by self-assembly of 11-mercaptoundecanoic acid, and the monomolecular layer is covalently coupled with an amino-modified single-stranded DNA molecule aptamer. The sensor can be used for detecting various protein molecules including IFN-gamma tumor markers.

The invention relates to the technical field of feature extraction, in particular to a feature extraction method and system for CAR-NK cell data, and the method comprises the following steps: collecting CAR-NK cell samples, carrying out protein analysis on the CAR-NK cell samples in batches, recording expression change of protein in each batch of CAR-NK cell samples, carrying out quantitative analysis on metabolite samples, and obtaining metabolite concentration data. And carrying out standardization treatment on the concentration data to obtain basic data of the cell sample. According to the method, the protein and the metabolite in the CAR-NK cell sample are quantitatively analyzed, the reaction characteristics of the cell in different immune environments can be comprehensively captured, the influence of the immune environments on the cell function is clarified through immune response grouping and clustering analysis, and the protein-metabolite interaction network reveals the interaction of molecules inside and outside the cell, so that the immunologic function of the cell is enhanced. By screening and verifying immune markers, an accurate immune function evaluation basis and quantitative analysis of immune reactivity characteristics are provided, the immune reaction process can be tracked in real time, and the research precision and depth are improved.

The invention discloses a method for quantifying tumor immune status based on radiomics, comprising the following steps: S1, collecting clinical information, immunohistochemical characteristics, overall survival period OS and disease-free survival period DFS of tumor patients; S2, obtaining Solid tumor CT image sample group; S3, randomly divide patients into training set and test set in proportion; S4, use immune markers to calculate immune score, and divide patients into high immune state and low immune state; S5, segment ROI , extract the radiomics features of solid tumors in the region of interest; S6, screen out the radiomics features related to the immune status from the radiomics features in the training set, and train the prediction model; S7, predict the imaging immune score of tumor patients, and get Image immune status, and then predict the patient's DFS and OS. The invention can use CT image features to predict the immune status of solid tumors such as colorectal cancer, lung cancer, gastric cancer and breast cancer, reducing or avoiding the analysis of pathological sections and immunohistochemistry.